Filing Details

Accession Number:
0000899243-16-027990
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-24 16:05:27
Reporting Period:
2016-08-22
Filing Date:
2016-08-24
Accepted Time:
2016-08-24 16:05:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1559053 Prothena Corp Plc PRTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1582306 J. Dennis Selkoe C/O Prothena Biosciences Inc
650 Gateway Boulevard
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value $0.01 Per Share Acquisiton 2016-08-22 5,000 $16.42 7,845 No 4 M Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2016-08-22 3,300 $54.39 4,545 No 4 S Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2016-08-22 1,700 $55.05 2,845 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (right to buy) Disposition 2016-08-22 5,000 $0.00 5,000 $16.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,500 2014-07-22 2023-07-21 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares, Par Value $0.01 Per Share 1,363 Indirect By wife
Footnotes
  1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $53.83 to $54.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The transaction was executed in multiple trades in prices ranging from $54.87 to $55.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.